DLBCL – Medxy AI

High Efficacy and Safety of Glofitamab Plus Polatuzumab-R-CHP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Multicenter Study

By MedXY 10/11/2026

A phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.

$Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL$

news Oncology

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

By MedXY 01/13/2026

The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, highlighting the complexity of overcoming resistance in the tumor microenvironment.

Hematology-Oncology news Oncology

Five-Year POLARIX Follow-Up: Polatuzumab-R-CHP Improves Long-Term PFS in Frontline DLBCL — What Clinicians Need to Know

By MedXY 12/11/2025

At five years, pola‑R‑CHP showed a sustained progression‑free survival benefit versus R‑CHOP in newly diagnosed intermediate‑/high‑risk DLBCL (HR 0.77), with similar long‑term tolerability and no statistically significant overall survival difference.